Stay updated with breaking news from Nasdaq Abus. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Kades & Cheifetz LLC bought a new position in shares of Arbutus Biopharma Co. (NASDAQ:ABUS – Free Report) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 20,000 shares of the biopharmaceutical company’s stock, valued at approximately $41,000. A number of […]
Clear Harbor Asset Management LLC grew its position in Arbutus Biopharma Co. (NASDAQ:ABUS – Free Report) by 148.6% in the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 131,761 shares of the biopharmaceutical company’s stock after purchasing an additional 78,761 shares during the period. Clear Harbor Asset Management LLC’s holdings in Arbutus Biopharma were worth […]
StockNews.com started coverage on shares of Arbutus Biopharma (NASDAQ:ABUS – Free Report) in a research report released on Thursday. The firm issued a hold rating on the biopharmaceutical company’s stock. Other equities research analysts have also issued reports about the stock. HC Wainwright reiterated a buy rating and set a $6.00 target price on shares […]
HC Wainwright reiterated their buy rating on shares of Arbutus Biopharma (NASDAQ:ABUS – Free Report) in a report published on Friday, Benzinga reports. They currently have a $6.00 target price on the biopharmaceutical company’s stock. Separately, StockNews.com lowered shares of Arbutus Biopharma from a buy rating to a hold rating in a research note on […]
WARMINSTER, Pa., June 07, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging...